# US 2010/0166898 A1 · Anti-bacterial use of extract from morus australis poir. and compound kuwanon h > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2010/0166898 A1 - Document ID: US20100166898A1 - Status: Published application - Kind: A1 - Application number: 12/345,254 - Filed: 2008-12-29 - Published: 2010-07-01 - Earliest claimed: 2008-12-29 - Assignees: Medical and Pharmaceutical Industry Technology and Development Center - Inventors: Yuan-Ling Ku; Shih-Tsun Liang; Yu-Hsuan Lin; Liang-Hua Chen; Ying-Yu Kuo - Web page: https://patentgrep.com/patent/US20100166898A1 ## CPC - A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} - A61P 31/04: Antibacterial agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract An extract prepared from the root barks of Morus australis Poir. and its use as an anti-bacteria agent, and use of a compound Kuwanon H having the following formula (I) separated from the extract as an anti-bacteria agent: ## Claims ### Claim 1 A method of treating a subject having a bacteria infection, which comprises administering to said subject a therapeutically effective amount of a compound having formula (I): or a pharmaceutically acceptable salt thereof. ### Claim 2 (depends on 1) The method according to claim 1, wherein the bacteria are Gram-positive bacteria. ### Claim 3 (depends on 1) The method according to claim 1, wherein the bacteria are Staphylococcus aureus (Smith) or Streptococcus pneumoniae. ### Claim 4 (depends on 3) The method according to claim 3, wherein the bacteria are Staphylococcus aureus (Smith). ### Claim 5 (depends on 4) The method according to claim 4, wherein the bacteria are Staphylococcus aureus, Methicillin Resistant. ### Claim 6 (depends on 3) The method according to claim 3, wherein the bacteria are Streptococcus pneumoniae. ### Claim 7 (depends on 6) The method according to claim 6, wherein the bacteria are Streptococcus pneumoniae, Erythromycin and Ampicillin Resistant. ### Claim 8 (depends on 1) A method of treating a subject having a bacteria infection, which comprises administering to said subject a therapeutically effective amount of an extract prepared from the root barks of Morus australis Poir., wherein the extract is prepared by a process comprising the following steps: a) extracting the root barks of Morus australis Poir. with a polar solvent; b) concentrating the resulting extract solution from step a); c) introducing the resulting concentrate from step b) to a reverse phase chromatography column, and eluting the column with a first eluent and a second eluent in sequence, said first eluent having a polarity of about 50 wt % of ethanol aqueous solution and said second eluent having a polarity of about 95 wt % of ethanol aqueous solution; and d) collecting a second eluate from the elution of the column with the second eluent, and removing the second eluent from the second eluate by evaporation; and the extract contains the compound of formula (I) as set forth in claim 1 and a compound having the following formula (II): ### Claim 9 (canceled) ### Claim 10 (depends on 8) The method according to claim 8, wherein the extract comprises 1-5% of the compound (I) and 1-5% of the compound (II), based on the weight of the extract. ### Claim 11 (depends on 10) The method according to claim 10, wherein the extract comprises about 3.7% of the compound (I) and 2.3% of the compound (II), based on the weight of the extract. ### Claim 12 (depends on 8) The method according to claim 8, wherein the first eluent is a 50 wt % ethanol aqueous solution and the second eluent is a 95 wt % ethanol aqueous solution. ### Claim 13 (canceled) ### Claim 14 (depends on 12) The method according to claim 12, wherein the polar solvent is 95 wt % ethanol aqueous solution. ### Claim 15 (depends on 8) The method according to claim 8, wherein the bacteria are Gram-positive bacteria. ### Claim 16 (depends on 8) The method according to claim 8, wherein the bacteria are Staphylococcus aureus (Smith) or Streptococcus pneumoniae. ### Claim 17 (depends on 16) The method according to claim 16, wherein the bacteria are Staphylococcus aureus (Smith). ### Claim 18 (depends on 17) The method according to claim 17, wherein the bacteria are Staphylococcus aureus, Methicillin Resistant. ### Claim 19 (depends on 16) The method according to claim 16, wherein the bacteria are Streptococcus pneumoniae. ### Claim 20 (depends on 19) The method according to claim 19, wherein the bacteria are Streptococcus pneumoniae, Erythromycin and Ampicillin Resistant. ### Claim 21 A method of treating a subject having a bacteria infection, which comprises administering to said subject a therapeutically effective amount of an isolated compound having formula (I): or a pharmaceutically acceptable salt thereof. ### Claim 22 (depends on 21) The method of claim 21, wherein the bacteria are Gram-positive bacteria. ### Claim 23 (depends on 21) The method of claim 21, wherein the bacteria are Staphylococcus aureus (Smith) or Streptococcus pneumoniae. ### Claim 24 (depends on 21) The method of claim 21, wherein the bacteria are Methicillin Resistant Staphylococcus aureus or Erythromycin and Ampicillin Resistant Streptococcus pneumoniae.